ANGPTL3 Inhibition: Assessing Therapeutic Value in Cholesterol Lowering and Triglyceride Control

A lipid therapy target rooted in genetic deficiency
Does ANGPTL3 inhibition offer its main therapeutic value by lowering cholesterol or by regulating triglyceride-rich lipoproteins? A review in Expert Opinion on Therapeutic Targets examined this question using genetic, mechanistic, and clinical trial evidence. It suggests that the degree of hypertriglyceridemia before treatment may influence drug response, but does not establish that higher triglyceride levels increase the effect of any particular agent.
Interest in angiopoietin-like protein 3 (ANGPTL3) as a therapeutic target began with cases of genetic deficiency in humans. People with inherited ANGPTL3 deficiency were observed to have lower triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). This pattern was also associated with protection from atherosclerotic cardiovascular disease (ASCVD). However, the protective effect observed with genetic deficiency cannot be interpreted as equivalent to cardiovascular disease prevention through drug treatment.
Multiple inhibition strategies and a central question still open
These genetic observations led to the development of several ANGPTL3 inhibition strategies. The review cites evinacumab, a monoclonal antibody; vupanorsen, an antisense oligonucleotide; and zodasiran and solbinsiran, small interfering RNAs (siRNAs). It also introduces the genome-editing approaches VERVE-201 and CTX310. The provided abstract does not include data for comparing the development stage, approval status, or duration of effect of each candidate.
The review’s central focus is the role ANGPTL3 inhibition plays in different lipid disorders, rather than the list of approaches itself. The authors present efficacy in homozygous familial hypercholesterolemia as an example of its value as a cholesterol-lowering target. They also examine whether its main therapeutic value lies in regulating triglyceride-rich lipoproteins and remnant cholesterol, with changes in LDL-C occurring as a secondary effect.
The degree of hypertriglyceridemia before treatment is mentioned as a factor that could influence drug response. However, the abstract does not specify the direction or magnitude of the response, or a threshold for distinguishing patients. It therefore does not support the conclusion that criteria have been established for predicting the extent of LDL-C reduction or choosing a particular drug based on triglyceride levels alone.
Distinguishing therapeutic potential from clinical proof
This paper is a review discussing the potential and limitations of ANGPTL3 based on existing evidence, rather than a clinical trial reporting treatment outcomes in a new patient group. Changes in lipid levels must therefore be distinguished from cardiovascular disease prevention, and genetic observations from drug treatment outcomes.
Future research could examine how drug response varies with baseline lipid status and what clinical significance changes in LDL-C and triglyceride-related measures each have. Genome editing is one of the approaches discussed, but this abstract does not provide grounds for claiming that a single dose produces a permanent effect or a cure. The available material does not report participant numbers, follow-up duration, or safety results for individual trials, making it difficult to determine whether one drug is superior to another.
Source: Bibliographic information and abstract for the ANGPTL3 therapeutic-target review indexed in Europe PMC.
INTRODUCTION: Angiopoietin-like protein 3 (ANGPTL3) has emerged over the past decade as one of the most intriguing therapeutic targets in lipid metabolism. AREAS COVERED: Genetic deficiency of ANGPTL3 in humans produces a striking pan-hypolipidemic phenotype, with reductions in triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), accompanied by protection from atherosclerotic cardiovascular disease (ASCVD). These observations rapidly catalyzed the development of pharmacologic strategies to inhibit ANGPTL3 using monoclonal antibodies (e.g. evinacumab), antisense oligonucleotides (e.g. vupanorsen), small interfering ribonucleic acid (e.g. zodasiran and solbinsiran), and most recently genome-editing approaches (e.g. VERVE-201 and CTX310). However, clinical experience has revealed a more complex and context-dependent biology than initially anticipated. EXPERT OPINION: This review examines whether ANGPTL3 should be considered a clinically meaningful cholesterol-lowering target, as exemplified by efficacy of ANGPTL3 inhibition in homozygous familial hypercholesterolemia, or whether its principal therapeutic value lies in modulation of triglyceride-rich lipoproteins and remnant cholesterol, with secondary effects on LDL-C. The degree of hypertriglyceridemia in the patient's baseline lipid profile appears to be an important determinant of drug response. Drawing on genetic, mechanistic, and clinical trial data, the promise and limitations of ANGPTL3 inhibition are considered and its potential place in future lipid-lowering strategies is outlined. A liver protein called ANGPTL3 has become one of the most promising drug targets for new cholesterol-lowering treatments. People born with a natural deficiency of this protein have unusually low levels of all blood fats – including triglycerides and both ‘bad’ (LDL) and ‘good’ (HDL) cholesterol – and are largely protected from heart disease. This sparked intense interest in de
Researchers developing ANGPTL3 inhibitors or designing clinical trials can use the review’s discussion to frame questions about patient groups and outcome measures. For example, they could compare responses among groups with different baseline triglyceride levels while separately assessing changes in LDL-C and in triglyceride-rich lipoproteins and remnant cholesterol. This is a direction for future validation, not an established patient-selection criterion. Efficacy in homozygous familial hypercholesterolemia should not be generalized to patients with other lipid disorders, nor should cardiovascular protection associated with genetic deficiency be treated as equivalent to a preventive effect of medication. The available abstract provides neither prescribing criteria nor a quantitative tool for predicting response.